Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

Journal of Infection and Chemotherapy

Volumn 20, Issue 1, 2014, Pages 1-5

  Okada, Kenji ^a,p   Kimura, Toshimi ^a,p   Mikamo, Hiroshige ^b,q   Kasahara, Kei ^c,q   Seki, Masafumi ^d,q   Takakura, Shunji ^e,q   Tokimatsu, Issei ^f,q   Ohmagari, Norio ^g,q   Takahashi, Yoshiko ^h,q   Matsumoto, Kazuaki ^i,q   Igarashi, Masahiro ^j,p   Kobayashi, Masahiro ^k,p   Hamada, Yukihiro ^b,p   Mochizuki, Takahiro ^l,p   Kimura, Masao ^m,p   Nishi, Yoshifumi ^n,p   Tanigawara, Yusuke ^o,q   Takesue, Yoshio ^h,q  

^a TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

^e KYOTO UNIVERSITY HOSPITAL   (Japan)

^f OITA UNIVERSITY   (Japan)

^g National Center for Global Health and Medicine   (Japan)

^h HYOGO COLLEGE OF MEDICINE HOSPITAL   (Japan)

ⁱ KAGOSHIMA UNIVERSITY   (Japan)

^j TORANOMON HOSPITAL   (Japan)

^k KITASATO UNIVERSITY HOSPITAL   (Japan)

^l SHIZUOKA CANCER CENTER   (Japan)

^m AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

ⁿ KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o KEIO UNIVERSITY   (Japan)

^p Sectional Committee of Practice Guidelines for TDM   (Japan)

^q Japanese Society of Chemotherapy   (Japan)

more..

Author keywords

Arbekacin; Guideline; MRSA; Therapeutic drug monitoring

Indexed keywords

HABEKACIN; ANTIINFECTIVE AGENT; DIBEKACIN;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; CONSENSUS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; HUMAN; JAPAN; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRACTICE GUIDELINE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STANDARDS; STAPHYLOCOCCAL INFECTIONS;

ANTI-INFECTIVE AGENTS; CONSENSUS; DIBEKACIN; DRUG MONITORING; HUMANS; JAPAN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 84903724636     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2013.08.008     Document Type: Article

References (29)

1. Kondo S, Iinuma K, Yamamoto H, Maeda K, Umezawa H. Syntheses of 1-n-((S)- 4-amino-2-hydroxybutyryl)-kanamycin B and -30,40-dideoxykanamycin B active against kanamycin-resistant bacteria. J Antibiot 1973;26:412-5
2. Aoki Y. Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus.Comparison ith that of vancomycin. Jpn J Antibiot 1994;47:640e6 (Pubitemid 24240153)
3. Hamilton-Miller JM, Shah S. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1995;35:865-8
4. Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K. Pharmacokinetic- pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:3763e9 (Pubitemid 44684891)
5. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001;52(Suppl. 1):35Se43S (Pubitemid 32823030)
6. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977;21:362e9 (Pubitemid 8064258)
7. Demczar DJ, Nafziger AN, Bertino Jr JS. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 1997;41:1115-9 (Pubitemid 27194194)
8. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1979;121:1193e254
9. Kobayashi M, Saikyo A, Soma K, Yago K, Sunakawa K. Pharmacokinetic and pharmacodynamic (PK-PD) analysis to determine the optimal method of arbekacin administration. Jpn J Chemother 2006;54:18-24 (Pubitemid 43246297)
10. Kawano H, Tanigawara Y. Postmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoring. Jpn J Ther Drug Monit 2010;27:55-71
11. Tanikaze N, Komatsu M, Shimakawa K, Yamamoto I. Study of clinical significance of PK/PD (pharmacokinetic/pharmacodynamic) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection. Jpn J Chemother 2004;52:469e73 (Pubitemid 39409654)
12. Aikawa N, Kohno S, Kaku M, Watanabe A, Yamaguchi K, Tanigawara Y. An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) d a clinical pharmacology study. Jpn J Chemother 2008;56:299e312 (Pubitemid 351795980)
13. Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K. Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:3754-62 (Pubitemid 44684890)
14. Ikeda K, Ikeda C, Katoh K, Tomiyama N, Matzno S, Matsuyama K, et al. Factors influencing peak concentrations of arbekacin in patients. Jpn J Pharm Health Care Sci 2009;35:701-5
15. Kobayashi M, Takesue Y, Tanigawara Y, Mikamo H, Kimura T, Hirata S, et al. Therapeutic drug monitoring survey of anti-MRSA agents in Japan. Jpn J Chemother 2010;58:119e24
16. Kimura T, Sunakawa K, Totsuka K, Matsumoto T, Hanaki H, Soma K, et al. Dose finding study on arbekacin sulfate for appropriate peak levels. Jpn J Chemother 2011;59:597-604
17. Yamamoto Y, Izumikawa K, Hashiguchi K, Fukuda Y, Kobayashi T, Kondo A, et al. The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients withMRSAinfection. J Infect Chemother 2012;18:241-6
18. Suzuki K. Efficacy and safety of arbekacin for staphylococcal infection in the NICU. Pediatr Int 2003;45:301-6 (Pubitemid 36995101)
19. Matsumoto T, Hanaki H, Kimura T, Nemoto M, Higashihara M, Yokota H, et al., ABK Dose Finding Study Group. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: A multi-institutional study. J Infect Chemother 2013;19:128-37
20. Traynor AM, Nafziger AN, Bertino Jr JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995;39:545-8
21. Sato N, Miura Y, Mitomi N, Hayashi H, Suzuki H, Shibasaki S, et al. Population pharmacokinetic analysis of arbekacin sulfate in adult patients. Jpn J Ther Drug Monit 2010;27:98-110
22. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14
23. Kimura T, Sato M, Nonoyama M, Yago K, Ishii M, Sunakawa K. Evaluation of initial dosage in neonates based on population pharmacokinetics of arbekacin. Jpn J Chemother 2006;54:520-5 (Pubitemid 44842822)
24. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 2004;48:1159e67 (Pubitemid 38405469)
25. Kinoshita D. Evaluation of once a day of arbekacin administration to neonates as a new object of peak concentration. J Jpn Assoc Infect Dis 2010;84:727-33
26. Place JD, Thompson SG, Clements HM, Ott RA, Jensen FC. Gentamicin substrate-labeled fluorescent immunoassay containing monoclonal antibody. Antimicrob Agents Chemother 1983;24:246-51
27. Farchione LA. Inactivation of aminoglycosides by penicillins. J Antimicrob Chemother 1981;8(Suppl. A):27-36 (Pubitemid 11043277)
28. Fuchs PC, Stickel S, Anderson PH, Barry AL, Shilling S. In vitro inactivation of aminoglycosides by sulbactam, other beta-lactams, and sulbactam-betalactam combinations. Antimicrob Agents Chemother 1991;35:182e4
29. Pickering LK, Gearhart P. Effect of time and concentration upon interaction between gentamicin, tobramycin, Netilmicin, or amikacin and carbenicillin or ticarcillin. Antimicrob Agents Chemother 1979;15:592e6. (Pubitemid 9152441)